Company intelligence / Profile preview

Averna Therapeutics

Boston, Massachusetts, United Statesthepharmaletter.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Averna Therapeutics is developing a platform to deliver redosable genomic medicines by inserting therapeutic genes into safe harbor sites in the genome using mRNA and LNP technology. The company has raised $82 million in Series A funding to advance its preclinical programs targeting a range of complex diseases. No clinical results have been published as of early 2025.[2][4][5]

Therapeutic areas: ImmunologyOncologyRare Diseases
Modalities: mRNA-based therapeuticsLipid nanoparticle (LNP) delivery systemsGenomic medicines (gene insertion)[2][4][5]
Industry: Biotech

Partnerships

CRISPR Therapeutics (investor/partner)[2][4]Novartis Venture Fund (investor/partner)

Beyond the preview

Go deeper on Averna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Averna Therapeutics.

Explore the full profile